Affini-T is a biotech company developing cell therapies to treat solid tumor cancers by targeting cancer-driving mutations, starting with KRAS. Their platform uses advanced engineering and synthetic biology to optimize T-cell functions and rewrite the rules of the tumor microenvironment for sustained clinical outcomes. The company is driven by world-class innovation and aims to develop transformational medicines.